Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apparent Diffusion Coefficient Histogram Analysis for Assessing Tumor Staging and Detection of Lymph Node Metastasis in Epithelial Ovarian Cancer: Correlation with p53 and Ki-67 Expression.
|
30456593 |
2019 |
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cell adhesion molecule profiles, proliferation activity and p53 expression in advanced epithelial ovarian cancer induced malignant ascites-Correlation of tissue microarray and cytology microarray.
|
29801775 |
2018 |
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
|
29301826 |
2018 |
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the association between lifestyle and reproductive factors and risk of ovarian cancer defined by p53 and MAPK expression.<b>Methods:</b> Epithelial ovarian cancer cases (<i>n</i> = 274) and controls (<i>n</i> = 1,907) were identified from the Nurses' Health Study and Nurses' Health Study II prospective cohorts, and the population-based New England Case-Control study.
|
29133366 |
2018 |
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis.
|
30178833 |
2018 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.
|
28148293 |
2017 |
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on its regulation of the tumor suppressor p53, RAD51-AS1-based therapy may represent a viable therapeutic option for EOC in the near future.
|
28667302 |
2017 |
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detecting an autologous antibody response to TP53 that might improve early detection.<b>Experimental Design:</b> An immunoassay was developed to measure TP53 autoantibody in sera from 378 cases of invasive epithelial ovarian cancer and 944 age-matched healthy controls from the United States, Australia, and the United Kingdom.
|
28637689 |
2017 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutation is a common event in EOC, particularly in high-grade serous ovarian cancer, where it occurs in more than 90% of cases.
|
26986846 |
2016 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy.
|
27209210 |
2016 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From October 2008 to February 2015, we established a hospital-based cohort of ovarian cancer patients and the germline status of all 218 women with invasive epithelial ovarian cancer was tested using targeted amplification and sequencing of the intron-exon junctions and exonic sequences of BRCA1, BRCA2, PALB2 and TP53.
|
26541979 |
2016 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.
|
26209050 |
2016 |
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, gene amplification, p53 and Rb disruption, and E2F1 activation drive FOXM1 expression in EOC, and FOXM1 promotes cell cycle progression in EOC cell models.
|
26243836 |
2015 |
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, misregulation of PLK1 coincident with P53 and P21WAF1 in EOC suggests poor prognosis.
|
25592872 |
2015 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed TP53 K351N mutations by allele specific real-time PCR (AS-PCR) and DNA sequencing in tumor samples of 153 patients with stage IIIC/IV EOC.
|
24463159 |
2014 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High-grade serous ovarian cancer (HG-SOC), a major histologic type of epithelial ovarian cancer (EOC), is a poorly-characterized, heterogeneous and lethal disease where somatic mutations of TP53 are common and inherited loss-of-function mutations in BRCA1/2 predispose to cancer in 9.5-13% of EOC patients.
|
24879340 |
2014 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in p53 were detected in 9 of the 16 EOCs: in 8 of these cases, the mutations were detected only in cancer cells.
|
23202778 |
2013 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 (Tumor Protein 53, previously known as p53) is probably the best known of all tumor suppressor genes, and is mutated in nearly all (96%) high-grade serous ovarian cancer (HGS-OvCa), which is the most common histopathological type of epithelial ovarian cancer (EOC).
|
23880140 |
2013 |
Epithelial ovarian cancer
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation in the p53 promoter in epithelial ovarian cancer.
|
22855178 |
2013 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.
|
23268330 |
2013 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations occurred frequently not only in high-grade serous carcinomas (58.7%), but also in mucinous (57%) and clear cell EOC (52%).
|
23965232 |
2013 |
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we examined the role of p53 status in EOC response to a novel combination of cisplatin, sodium arsenite, and hyperthermia.
|
22331493 |
2012 |
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.
|
21903246 |
2011 |
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
miR-34a expression is decreased in 100%, and miR-34b*/c in 72%, of EOC with p53 mutation, whereas miR-34a is also downregulated in 93% of tumors with wild-type p53.
|
20145172 |
2010 |
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to evaluate the prognostic significance of p53 and PTEN in patients with epithelial ovarian cancer who were treated with taxane and platinum-based chemotherapy.
|
19150122 |
2009 |